X4 Pharmaceuticals (XFOR) said Friday that its marketing authorization application for mavorixafor to treat WHIM syndrome has been validated for review by the European Medicines Agency.
The EMA previously granted mavorixafor orphan drug designation to treat WHIM syndrome, a rare genetic disease that impairs the body's immune system and is characterized by recurrent infections, skin warts, and an increased risk of cancer.
The treatment is sold in the US under the Xolremdi brand name following approval last April by the US Food and Drug Administration to treat WHIM syndrome in patients 12 years of age and older.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。